Effimune SAS is a biotech company that creates drug candidates for transplantation and immune-mediated diseases. The company's solutions include monoclonal antibodies that deplete effector T lymphocytes without altering Treg, neutralize cytokines implied in various auto-immune diseases, and block effector T cell responses while amplifying Treg responses. Effimune SAS is engaged in the research and development of biological drug candidates that regulate the immune system in organ and tissue transplantation, as well as auto-immune diseases, to restore the balance between effector and regulatory mechanisms.